Kyogo Itoh
Kyogo Itoh, Miyaki-Gun JP
Patent application number | Description | Published |
---|---|---|
20090297544 | NOVEL TUMOR ANTIGEN PROTEIN SART-3 AND TUMOR ANTIGEN PEPTIDES THEREOF - A novel tumor antigen protein and gene therefor, tumor antigen peptides derived from said tumor antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumors using such tumor substances in vitro or in vitro are provided. | 12-03-2009 |
20100292138 | Peptide Derived from Hepatitis C Virus - Disclosed is a pharmaceutical composition for the treatment of an HCV-related disease in a patient having HLA-A24 or -A3 supertype, wherein the pharmaceutical composition comprises a peptide having an amino acid sequence represented by the formula: YLLPRRGPRL (SEQ ID NO:1) as an active ingredient. Also disclosed is a composition for use in the detection of the induction of an HLA-A24 or -A3 supertype-restricted cytotoxic T cell in a patient having HLA-A24 or -A3 supertype, wherein the composition comprises a peptide having an amino acid sequence depicted in SEQ ED NO:1 as an active ingredient. | 11-18-2010 |
20110243974 | NOVEL TUMOR ANTIGEN PROTEIN SART-3 AND TUMOR ANTIGEN PEPTIDES THEREOF - A novel tumor antigen protein and gene therefor, tumor antigen peptides derived from said tumor antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumors using such tumor substances in vitro or in vitro are provided. | 10-06-2011 |
20120123090 | NOVEL TUMOR ANTIGEN PROTEIN SART-3 AND TUMOR ANTIGEN PEPTIDES THEREOF - A novel tumor antigen protein and gene therefor, tumor antigen peptides derived from said tumor antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumors using such tumor substances in vitro or in vitro are provided. | 05-17-2012 |
Kyogo Itoh, Fukuoka-Ken JP
Patent application number | Description | Published |
---|---|---|
20100278851 | CTL INDUCER COMPOSITION - The present invention provides a CTL inducer composition which comprises one or more peptides selected from the group consisting of the peptides of SEQ ID NOS: 1 to 27 in the Sequence Listing, and can be used for the treatment or prevention of cancer or a hepatitis C virus-related disease in two or more patient groups selected from the group consisting of an HLA-A2 positive patient group, an HLA-A24 positive patient group, an HLA-A26 positive patient group, and an HLA-A3 supertype positive patient group. | 11-04-2010 |
Kyogo Itoh, Saga-Ken JP
Patent application number | Description | Published |
---|---|---|
20080254445 | Prognosis in Cancer Patients Vaccinated with a Cancer Antigen Peptide-Associated Agent - The correlation of clinical benefits and immune responses to peptides in cancer patients who were vaccinated with CTL-directed peptides is shown. The invention relates to a process for determining prognosis in a cancer patient vaccinated with a cancer antigen peptide-associated agent, which comprises measuring a level of an antibody specific to the cancer antigen peptide, and assessing whether the level is significantly increased as compared to the level at pre-vaccination. | 10-16-2008 |
20080286313 | Peptide Vaccines for the Treatment of Cancers - The present invention provides a method for treating a cancer patient which comprises administering a therapeutically effective amount of a cancer antigen peptide to the patient in need thereof, wherein the method comprises the steps of | 11-20-2008 |
20090312264 | Squamous Cell Carcinoma Antigen-Derived Peptide Binding to HLA-A24 Molecule - Provided is a squamous cell carcinoma antigen derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of squamous cell carcinoma. | 12-17-2009 |
20100184699 | Peptide Derived From Prostate-Related Protein As Cancer Vaccine Candidate For Prostate Cancer Patient Who Is Positive For Hla-A3 Super-Type Allele Molecule - According to the present invention, a peptide, which is a prostate-related protein derived peptide, capable of binding to an HLA-A3 supertype allele and recognized by the cellular and/or humoral immune system is provided. The peptides of the present invention make feasible the peptide-based anti-cancer vaccine therapy for prostate cancer patients with HLA-A3 supertype allele and useful for the treatment of prostate cancer patients with alleles other than HLA-A2 and -A24 to which cancer vaccine peptide candidates had been identified. | 07-22-2010 |
Kyogo Itoh, Fukuoka JP
Patent application number | Description | Published |
---|---|---|
20100074912 | HILA-A24-BINDING KEF-DERIVED PEPTIDE - An object of the invention is to provide a peptide derived from a glioma-associated antigen being useful for the specific immunotherapy for glioma patients. The invention provides a KIF-derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of glioma. | 03-25-2010 |
Kyogo Itoh, Saga JP
Patent application number | Description | Published |
---|---|---|
20100015169 | Tumor Antigens - Tumor antigen peptides that induce CTL from peripheral blood mononuclear cells of a patient with prostate cancer in an HLA-A2-restricted or an HLA-A24-restricted manner were identified based on the amino acid sequences of PSA, PSM, and PSCA, which are proteins known as markers of prostate cancer. Also disclosed is a peptide having a function as a tumor antigen that is recognized by HLA-A2-restricted CTL or HLA-A24-restricted CTL, an antibody against the peptide, a compound having interaction with the peptide, an agent for inducing CTL that includes the peptide, a pharmaceutical composition that includes one or more thereof, a method for identifying a compound that has interaction with the peptide, a method for inducing CTL using the peptide, a method for measuring the peptide and the antibody, as well as a reagent kit used for the identification method or the measurement method. | 01-21-2010 |
Kyogo Itoh, Kurume-Shi JP
Patent application number | Description | Published |
---|---|---|
20130023432 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF IMMUNOTHERAPY ON CANCER PATIENT AND/OR PROGNOSIS AFTER IMMUNOTHERAPY, AND GENE SET AND KIT TO BE USED THERIN - The present invention provides a method for predicting effect of immunotherapy on a cancer patient and/or prognosis of the cancer patient after the immunotherapy, and a gene set and a kit for use in the method. | 01-24-2013 |
20130157893 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF IMMUNOTHERAPY ON CANCER PATIENT, AND GENE SET AND KIT TO BE USED IN THE METHOD - Provided is a gene set which is useful for predicting the therapeutic effect of an immunotherapy on a cancer patient. Also provided is a method for examining whether an immunotherapy is efficacious or not, said method comprising quantifying the expression amount of each of the genes constituting the aforesaid gene set. This examination method is useful for determining a therapeutic strategy for the cancer patient. | 06-20-2013 |
20130164314 | CANCER PEPTIDE VACCINE - A composition for treating cancer, comprising 6 to 13 peptides derived from tumor antigens, wherein the composition is used in the manner that antibodies to the respective peptides in the peripheral blood of a patient are measured and peptides to which antibodies are positive are selected and administered to the patient, and a peptide selection method. | 06-27-2013 |